Independent from each other, two uncontrolled open-label trials investigated the clinical efficacy and safety of a low-dose IL-2 regimen with aldesleukin in patients with hepatitis C-associated vasculitis and graft-versus-host disease (GvHD), respectively (47, 48). Here, IL2 is linked to graft versus host disease.